Article Open Access

Comprehensive Landscape of Matrix Metalloproteinases in the Pathogenesis of Idiopathic Pulmonary Fibrosis

Fibrosis. 2023, 1(1), 10004;
State Key Laboratory of Cell Differentiation and Regulation, Henan International Joint Laboratory of Pulmonary Fibrosis, Henan Center for Outstanding Overseas Scientists of Pulmonary Fibrosis, College of Life Science, Institute of Biomedical Science, Henan Normal University, Xinxiang 453007, China
Authors to whom correspondence should be addressed.

Received: 30 Mar 2023    Accepted: 28 Apr 2023    Published: 19 May 2023   


Idiopathic pulmonary fibrosis (IPF) is a progressive, chronic interstitial lung disease with unknown etiology. Matrix metalloproteinases (MMPs) are involved in fibrotic lung tissues, contributing to the initiation, progression, or resolution of chronic inflammatory disease. In present study, comprehensive changes of MMPs expressions were investigated in IPF by integrative analysis of single-cell transcriptome and bulk transcriptome data. 24 of MMPs were altered and the changes could significantly distinguish IPF from normal subjects and other lung diseases. Among them, MMP1, MMP7 and MMP19 were closely associated to lung functions, susceptibility and alveolar surface density. MMP1 and MMP7 as potential diagnostic indicators, MMP1 and MMP19 as prognostic markers in IPF could accurately predict disease progression. Devolution of MMPs at single-cell resolution, MMP19 was highly expressed in macrophages and markedly interfered with TNF signaling pathway which synchronizes fibrotic microenvironment. MMP19+ macrophages were significantly different from MMP19- macrophages in energy metabolism and immune function. The interaction of MMP19+ macrophages with hyperplastic AT2 was mediated by TNFSF12-TNFRSF12A, and further activated the TNFRSF12A receptor to affect cell glucose metabolism and mitochondrial function. In summary, MMPs has great application potential in the diagnosis, treatment, and prognosis of IPF.


Richeldi L, Collard HR, Jones MG. Idiopathic pulmonary fibrosis.  Lancet 2017, 389, 1941–1952. [Google Scholar]
Barratt SL, Creamer A, Hayton C, Chaudhuri N. Idiopathic Pulmonary Fibrosis (IPF): An Overview.  J. Clin. Med. 2018, 7, 201. [Google Scholar]
Sgalla G, Iovene B, Calvello M, Ori M, Varone F, Richeldi L. Idiopathic pulmonary fibrosis: pathogenesis and management.  Respir. Res. 2018, 19, 32. [Google Scholar]
Craig VJ, Zhang L, Hagood JS, Owen CA. Matrix metalloproteinases as therapeutic targets for idiopathic pulmonary fibrosis.  Am. J. Respir. Cell Mol. Biol. 2015, 53, 585–600. [Google Scholar]
Dancer RC, Wood AM, Thickett DR. Metalloproteinases in idiopathic pulmonary fibrosis.  Eur. Respir. J. 2011, 38, 1461–1467. [Google Scholar]
Cui N, Hu M, Khalil RA. Biochemical and Biological Attributes of Matrix Metalloproteinases.  Prog. Mol. Biol. Transl. Sci. 2017, 147, 1–73. [Google Scholar]
Yue L, Shi Y, Su X, Ouyang L, Wang G, Ye T. Matrix metalloproteinases inhibitors in idiopathic pulmonary fibrosis: Medicinal chemistry perspectives.  Eur. J. Med. Chem. 2021, 224, 113714. [Google Scholar]
Mahalanobish S, Saha S, Dutta S, Sil PC. Matrix metalloproteinase: An upcoming therapeutic approach for idiopathic pulmonary fibrosis.  Pharmacol. Res. 2020, 152, 104591. [Google Scholar]
Hong M, Tao S, Zhang L, Diao LT, Huang X, Huang S, et al. RNA sequencing: new technologies and applications in cancer research.  J. Hematol. Oncol. 2020, 13, 166. [Google Scholar]
Konigsberg IR, Borie R, Walts AD, Cardwell J, Rojas M, Metzger F, et al. Molecular Signatures of Idiopathic Pulmonary Fibrosis.  Am. J. Respir. Cell Mol. Biol. 2021, 65, 430–441. [Google Scholar]
Yin Q, Strong MJ, Zhuang Y, Flemington EK, Kaminski N, De Andrade JA, et al. Assessment of viral RNA in idiopathic pulmonary fibrosis using RNA-seq.  BMC Pulm. Med. 2020, 20, 81. [Google Scholar]
Yang IV, Coldren CD, Leach SM, Seibold MA, Murphy E, Lin J, et al. Expression of cilium-associated genes defines novel molecular subtypes of idiopathic pulmonary fibrosis.  Thorax 2013, 68, 1114–1121. [Google Scholar]
Yu G, Tzouvelekis A, Wang R, Herazo-Maya JD, Ibarra GH, Srivastava A, et al. Thyroid hormone inhibits lung fibrosis in mice by improving epithelial mitochondrial function.  Nat. Med. 2018, 24, 39–49. [Google Scholar]
Furusawa H, Cardwell JH, Okamoto T, Walts AD, Konigsberg IR, Kurche JS, et al. Chronic Hypersensitivity Pneumonitis, an Interstitial Lung Disease with Distinct Molecular Signatures.  Am. J. Respir. Cell Mol. Biol. 2020, 202, 1430–1444. [Google Scholar]
McDonough JE, Ahangari F, Li Q, Jain S, Verleden SE, Herazo-Maya J, et al. Transcriptional regulatory model of fibrosis progression in the human lung.  JCI Insight 2019, 4, e131597. [Google Scholar]
Sivakumar P, Thompson JR, Ammar R, Porteous M, Mccoubrey C, Cantu E 3rd, Ravi K, et al. RNA sequencing of transplant-stage idiopathic pulmonary fibrosis lung reveals unique pathway regulation.  ERJ Open Res. 2019, 5, 00117-2019. [Google Scholar]
Habermann AC, Gutierrez AJ, Bui LT, Yahn SL, Winters NI, Calvi CL, et al. Single-cell RNA sequencing reveals profibrotic roles of distinct epithelial and mesenchymal lineages in pulmonary fibrosis.  Sci. Adv. 2020, 6, eaba1972. [Google Scholar]
Prasse A, Binder H, Schupp JC, Kayser G, Bargagli E, Jaeger B, et al. BAL Cell Gene Expression Is Indicative of Outcome and Airway Basal Cell Involvement in Idiopathic Pulmonary Fibrosis. Am. J. Respir. Crit. Care Med. 2019, 199, 622–630. [Google Scholar]
Iacono G, Massoni-Badosa R, Heyn H. Single-cell transcriptomics unveils gene regulatory network plasticity.  Genome Biol. 2019, 20, 110. [Google Scholar]
Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks.  Genome Res. 2003, 13, 2498–2504. [Google Scholar]
Peng L, Wen L, Shi QF, Gao F, Huang B, Meng J, et al. Scutellarin ameliorates pulmonary fibrosis through inhibiting NF-κB/NLRP3-mediated epithelial-mesenchymal transition and inflammation.  Cell Death Dis. 2020, 11, 978. [Google Scholar]
Rosas IO, Richards TJ, Konishi K, Zhang Y, Gibson K, Lokshin AE, et al. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med. 2008, 5, e93. [Google Scholar]
Yu G, Kovkarova-Naumovski E, Jara P, Parwani A, Kass D, Ruiz V, et al. Matrix metalloproteinase-19 is a key regulator of lung fibrosis in mice and humans.  Am. J. Respir. Crit. Care Med. 2012, 186, 752–762. [Google Scholar]
Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.  Am. J. Respir. Crit. Care Med. 2018, 198, e44–e68. [Google Scholar]
Drakopanagiotakis F, Wujak L, Wygrecka M, Markart P. Biomarkers in idiopathic pulmonary fibrosis.  Matrix Biol. 2018, 68, 404–421. [Google Scholar]
Rozenberg D, Sitzer N, Porter S, Weiss A, Colman R, Reid WD, et al. Idiopathic Pulmonary Fibrosis: A Review of Disease, Pharmacological, and Nonpharmacological Strategies With a Focus on Symptoms, Function, and Health-Related Quality of Life.  J. Pain Symptom Manage 2020, 59, 1362–1378. [Google Scholar]
Collins MK, Shotland AM, Wade MF, Atif SM, Richards DK, Torres-Llompart M, et al. A role for TNF-α in alveolar macrophage damage-associated molecular pattern release.  JCI Insight 2020, 5, e134356. [Google Scholar]
Bormann T, Maus R, Stolper J, Tort Tarrés M, Brandenberger C, Wedekind D, et al. Role of matrix metalloprotease-2 and MMP-9 in experimental lung fibrosis in mice.  Respir Res. 2022, 23, 180. [Google Scholar]
Creative Commons

© 2024 by the authors; licensee SCIEPublish, SCISCAN co. Ltd. This article is an open access article distributed under the CC BY license (